Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21028328 | 0.84 | KCNH2 (0.35) | PTGDR2PTGDR | |
| SCHEMBL21027841 | 0.84 | PTGDR2 (0.36) | PTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL21027844 | 0.77 | PTGDR2 (0.41) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL21027980 | 0.74 | PTGDR2 (0.39) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL21028283 | 0.71 | HTR2A (0.45) | PTGDR2 | |
| SCHEMBL21027872 | 0.64 | PTGDR2 (0.43) | PTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL21027854 | 0.62 | PTGDR2 (0.46) | PTGDR2PTGDRTBXA2RCYP2C9 | |
| SCHEMBL21028326 | 0.62 | PTGDR2 (0.41) | PTGDR2PTGDRTBXA2RCYP3A4 | |
| SCHEMBL30106653 | 0.60 | CYP3A4 (0.37) | CYP2C9CYP3A4 | |
| SCHEMBL263863 | 0.59 | GABRP (0.56) | CYP2C9GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-12-13 | — | — | US | disclosed |
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| EP-3489235-A1 | TRICYCLIC COMPOUND AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | NR3C2, CRHR2, CRHR1 | PTGDR2 152/4885PTGDR 412/4885TBXA2R 184/4885 |
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | NR1H2, NR3C2, NR1H4 | PTGDR2 313/4885PTGDR 550/4885TBXA2R 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.